TWELVE MONTHS OF EMICIZUMAB PROPHYLAXIS IN A SEVERE HAEMOPHILIA A MAN WITH INHIBITOR WHO FAILED IMMUNE TOLERANCE INDUCTIONS: EFFECTIVENESS, ECONOMIC OUTCOME, AND SAFETY